Compare IOVA & MQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | MQ |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2008 | 2021 |
| Metric | IOVA | MQ |
|---|---|---|
| Price | $14.29 | $16.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 10 |
| Target Price | ★ $9.00 | $5.36 |
| AVG Volume (30 Days) | ★ 11.4M | 688.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $624,884,000.00 |
| Revenue This Year | $47.74 | $16.89 |
| Revenue Next Year | $40.31 | $16.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 23.25 |
| 52 Week Low | $1.76 | $3.70 |
| 52 Week High | $11.17 | $18.69 |
| Indicator | IOVA | MQ |
|---|---|---|
| Relative Strength Index (RSI) | 85.96 | 59.10 |
| Support Level | $3.57 | $16.52 |
| Resistance Level | N/A | $17.46 |
| Average True Range (ATR) | 0.67 | 0.42 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 99.84 | 83.02 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.